CORALreef Outcomes-TIMI 77

CORALreef Outcomes-TIMI 77 is a phase 3, randomized, placebo-controlled study of the efficacy and safety of MK-0616, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in 14,550 participants with high cardiovascular risk. The primary objective is to evaluate the efficacy of MK-0616 compared with placebo in increasing the time to the first occurrence of major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemia or major amputation, or urgent arterial revascularization.


CORALreef Outcomes on



%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close